{
    "clinical_study": {
        "@rank": "116010", 
        "arm_group": {
            "arm_group_label": "Rifampicin", 
            "arm_group_type": "Experimental", 
            "description": "experimentally check a change of the colchicine concentration from baseline at 1,2,4,8,24 hours after taking Rifampicin"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the colchicine concentration before and after the\n      administration of rifampicin."
        }, 
        "brief_title": "A Pilot Study for Pharmacokinetic Parameter of Colchicine in Patient Taking Rifampin", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Chronic Kidney Disease", 
            "Tuberculosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Tuberculosis", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  from 18yrs to 80yrs , man and women\n\n          -  the patient who are taking rifampicine over 2weeks\n\n          -  the patient sign on the concent form\n\n        Exclusion Criteria:\n\n          -  the patient have experience to take medication that have an effect on renal function\n\n          -  the patient have hypersensitivity to colchicine\n\n          -  At least, the average level of two separate blood pressure ( 2min interval ) shows\n             that SBP <= 100 mmHg or >=160 mmHg and DBP <=60 mmHg >=100 mmHg, or Heart rate < 40\n             beats/min or > 90 beats/min\n\n          -  uncontrolled hypertension\n\n          -  serum albumin < 3.5, > 5 g/dL\n\n          -  acute hepatitis or the level of AST or ALT is over 2times of normal range or the\n             level of bilirubin is over 2.0 mg/dL\n\n          -  the patient who have gastro-intestinal disease ( ex, crohn's disease, acute or\n             chronic pancreatitis, ulcer )or who have the surgical history of gastrointestine.\n\n          -  the patient who should take azathioprine, mercaptopurine, cyclophosphamide, Losartan,\n             benzbromarone,fenofibrate,furosemide ,probenecid\n\n          -  the patient who had taken part in the other study within 3months\n\n          -  the patient who had gotten blood transfusion\n\n          -  pregnant, breast feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "2", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 7, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932268", 
            "org_study_id": "Colchicine_RFP 2011_1"
        }, 
        "intervention": {
            "arm_group_label": "Rifampicin", 
            "description": "single arm : check a change of Colchicine concentrations from basline at 1,2,4,8,24 hours after Rifampicin administration", 
            "intervention_name": "Rifampicin", 
            "intervention_type": "Drug", 
            "other_name": "Rifampin"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Colchicine", 
                "Rifampin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 26, 2013", 
        "number_of_arms": "1", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "a change of the colchicine concentration from baseline at 1,2,4,8,24 hours after Rifampicin administration", 
            "safety_issue": "No", 
            "time_frame": "the colchicine concentration of baseline(C0) and at 1(C1),2(C2),4(C4),8(C8),24(C24) hours after Rifampicin administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932268"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}